Personalis, Inc.

🚨ICYMI: Last week we announced the expansion and extension of our strategic collaboration with @TempusAI. Personalis and Tempus will now work to bring to market the NeXT Personal® ultrasensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in…

📑 Check out this piece in National Geographic Health that highlights circulating tumor DNA (ctDNA) blood tests, such as NeXT Personal®, which can detect cancer recurrence earlier than traditional imaging scans. 🧬 NeXT Personal, an ultrasensitive ctDNA test, can detect very…

“The fact that we’ve seen every single recurrence being detected with ctDNA before clinical recurrence, and the fact that we haven’t seen any recurrences in patients who have surveillance samples that are negative is really impactful to say that [NeXT Personal®] is a test that…

🧬 @LucCabelMD highlights key takeaways from the SCANDARE trial (#TripleNegativeBreastCancer) in which detection with NeXT Personal®, an ultrasensitive circulating tumor DNA (ctDNA) test, improved prognostication in early-stage triple negative breast cancer (TNBC)…

We’re excited to be attending the 4th Annual Liquid Biopsy for #PrecisionOncology Summit East Coast! 🗣 Check out a talk by Kate Cunningham, PhD, Field Applications Scientist, Personalis, highlighting how NeXT Personal® can accelerate decisions in drug development through trial…

“Using [the NeXT Personal®] ultrasensitive [ctDNA] assay was both predictive and prognostic for locally advanced cervical cancer, and patients who had positive ctDNA after their treatment cycle of chemotherapy, radiation, and durvalumab or placebo… did worse in terms of…

This month and year-round, we are proud to be an ally to the LGBTQIA+ community. At Personalis, we welcome, encourage, support, and celebrate diverse voices and experiences. We are committed to creating a workplace where everyone feels safe and supported. #PrideMonth

📊 We presented groundbreaking NEW data in locally advanced #CervicalCancer (LACC) at #ASCO25. 🧬 Our ultrasensitive ctDNA blood test, NeXT Personal®, detected cancer relapse up to ~16 months ahead of imaging in a cohort of 186 patients with LACC. 📑 Read the following articles…

No Doubt: Ultrasensitive ctDNA Blood Test Sets Bar for MRD Cervical Cancer Phase 3 results indicate that the ultrasensitive NeXT Personal #ctDNA enables earlier detection in #cervicalcancer with high recurrence rates @UCSanDiego @PersonalisInc hubs.li/Q03rvfz40

🚨NEW results from #ASCO25: Our ultrasensitive NeXT Personal® #ctDNA blood test detected cervical cancer relapse up to ~16 months ahead of imaging in a cohort of 186 patients with locally advanced #CervicalCancer in latest CALLA phase 3 study analysis. Key findings: •…

🚨NEW DATA from #ASCO25! PREDICT DNA and SCANDARE studies highlight capabilities of ultrasensitive NeXT Personal® #ctDNA blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (#TNBC), one of the most aggressive types of…

#ASCO25: PREDICT-DNA study shows ctDNA testing after neoadjuvant chemo can identify HER2+/TNBC patients at highest recurrence risk - particularly important for TNBC cases. Could help identify who needs more treatment post-surgery. @UWMedicine @fredhutch

We're only a couple days away from our evening celebration! Space will be limited, make sure to RSVP soon. You can register for the event here: bit.ly/3T0DlEx.

⏯️ Check out this new video showing the ability of NeXT Personal® to consistently achieve highly sensitive limits of detection (LOD) across a large number of patient samples across many solid tumor types, including samples of poor quality: • NeXT Personal demonstrated a…

We’re pleased to announce an evening celebration for our patients, partners, collaborators, and customers during #ASCO25! The evening will feature live entertainment, beverages and heavy hors d’oeuvres with amazing panoramic views of the Chicago skyline. Plus, a speaking…